Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
CAMA-1 | Dinaciclib | pan CDK | Cell cycle | 0.014558 | -0.4849 | 0.6062 | 0.1927 | 2.0283 | 0.019954 | 0.99839 |
HCC70 | Dasatinib | BCR/ABL | MAPK/nRTK | 0.0096376 | -0.5787 | 1.0609 | 0.1267 | 1.0559 | 0.020015 | 0.98982 |
HME1 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.033475 | 0.1969 | 0.4005 | 0.0164 | 1.3589 | 0.020278 | 0.99162 |
CAMA-1 | Doxorubicin | Chemo | Chemotherapy | 0.0074655 | -0.6517 | 0.8426 | 0.2593 | 0.7583 | 0.020458 | 0.96039 |
HCC1143 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.9185 | 0.0347 | 0.0040 | 4.9981 | 0.020639 | 0.76284 |
MDA-MB-468 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.023529 | 0.0573 | 0.5025 | 0.1038 | 1.2151 | 0.020647 | 0.99651 |
PDX1328 | Palbociclib | CDK4/6 | Cell cycle | 0.028878 | 0.1110 | 0.4289 | -0.0020 | 1.3039 | 0.020889 | 0.9674 |
T47D | Dinaciclib | pan CDK | Cell cycle | 0.019853 | -0.2109 | 0.4815 | 0.0484 | 5.0000 | 0.021113 | 0.99494 |
HCC1806 | Doxorubicin | Chemo | Chemotherapy | 0.015898 | -0.3241 | 0.6281 | 0.1971 | 1.0948 | 0.021206 | 0.97525 |
PDX1258 | AZD7762 | CHK1/2 | Cell cycle | 0.014946 | -0.4528 | 0.9199 | 0.3234 | 1.6838 | 0.021221 | 0.99249 |
MDA-MB-436 | Trametinib | MEK | MAPK/nRTK | Inf | 0.5572 | 0.1820 | 0.0015 | 1.0351 | 0.021252 | 0.93697 |
PDX1328 | Doxorubicin | Chemo | Chemotherapy | 0.013267 | -0.7789 | 0.8023 | 0.1468 | 1.4934 | 0.021574 | 0.96338 |
HCC1500 | Topotecan | Topo I | Chemotherapy | 0.0054632 | -0.8011 | 1.2171 | 0.1857 | 0.7137 | 0.022012 | 0.99509 |
HCC1428 | Topotecan | Topo I | Chemotherapy | 0.010613 | -0.3764 | 0.8345 | 0.1405 | 0.6324 | 0.02202 | 0.8529 |
HCC1500 | ABT-737 | Bcl2/XL | Misc | 0.0085142 | -0.7359 | 1.1288 | 0.3716 | 0.9283 | 0.022222 | 0.99554 |
CAL-85-1 | Topotecan | Topo I | Chemotherapy | 0.015768 | -0.2957 | 0.8426 | 0.2732 | 1.2311 | 0.02233 | 0.99293 |
T47D | Palbociclib | CDK4/6 | Cell cycle | 0.027507 | 0.1166 | 0.4501 | 0.0077 | 1.5536 | 0.022367 | 0.99262 |
HCC1428 | Dinaciclib | pan CDK | Cell cycle | 0.017078 | -0.6716 | 0.6610 | 0.2408 | 2.9825 | 0.02239 | 0.9979 |
SUM159PT | Doxorubicin | Chemo | Chemotherapy | 0.019121 | -0.2740 | 0.6068 | 0.2965 | 1.5857 | 0.022541 | 0.98806 |
SUM1315MO2 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.015037 | -0.0903 | 0.4863 | 0.0621 | 0.7079 | 0.022637 | 0.99665 |
HCC1419 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 0.0091784 | -0.4046 | 0.8523 | 0.0945 | 0.5809 | 0.022714 | 0.98223 |
MDA-MB-468 | Topotecan | Topo I | Chemotherapy | 0.015779 | -0.6577 | 1.0692 | 0.4464 | 2.1036 | 0.023029 | 0.99528 |
MDA-MB-157 | Dinaciclib | pan CDK | Cell cycle | 0.017724 | -0.9106 | 0.7675 | 0.3195 | 3.8857 | 0.023072 | 0.99901 |
HCC1395 | Trametinib | MEK | MAPK/nRTK | 0.17156 | 0.4498 | 0.1903 | 0.0218 | 1.7439 | 0.023111 | 0.97973 |
MCF 10A | Volasertib | PLK | Cell cycle | 0.022128 | -0.0887 | 0.4466 | 0.1711 | 3.5358 | 0.023168 | 0.99997 |